Biomerica (NASDAQ:BMRA) Share Price Crosses Below Two Hundred Day Moving Average – Here’s What Happened

Biomerica, Inc. (NASDAQ:BMRA) shares crossed below its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $2.67 and traded as low as $2.06. Biomerica shares last traded at $2.10, with a volume of 12,929 shares.

Biomerica Trading Down 3.2%

The company has a 50-day moving average of $2.46 and a 200-day moving average of $2.67. The firm has a market capitalization of $6.34 million, a price-to-earnings ratio of -2.26 and a beta of 0.19.

Biomerica (NASDAQ:BMRA) last released its quarterly earnings data on Wednesday, January 14th. The company reported ($0.45) EPS for the quarter. Biomerica had a negative return on equity of 83.73% and a negative net margin of 90.29%.The business had revenue of $1.21 million during the quarter.

Institutional Investors Weigh In On Biomerica

A hedge fund recently raised its stake in Biomerica stock. DRW Securities LLC boosted its holdings in Biomerica, Inc. (NASDAQ:BMRA) by 62.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 16,925 shares of the company’s stock after acquiring an additional 6,533 shares during the period. DRW Securities LLC owned about 0.56% of Biomerica worth $43,000 at the end of the most recent quarter. Institutional investors own 22.28% of the company’s stock.

About Biomerica

Biomerica, Inc is a developer, manufacturer and marketer of in vitro diagnostic tests for clinical diagnostic, life science research and food safety applications. The company’s product portfolio includes enzyme-linked immunosorbent assays (ELISAs), lateral flow immunoassays, point-of-care devices and specialty reagents designed to aid in the detection and monitoring of gastrointestinal, metabolic and autoimmune conditions. Biomerica’s diagnostics are used by hospitals, clinical and reference laboratories, and research institutions seeking solutions for early disease detection and patient management.

Key offerings from Biomerica include serological tests for celiac disease and gluten intolerance, quantitative assays for colorectal cancer screening markers such as M2-PK, and a range of point-of-care kits for metabolic monitoring.